In 2023, we are expecting a bunch of new vaccines. A couple of them will target malaria, tuberculosis and genital herpes. Pfizer and BioNTech started their clinical trial study in November 2022. They developed this vaccine that will target the original SARS-CoV-2 to variants of American plus four variants of the influenza. And as well as these conventional mRNA vaccines, we were also likely to see things like fast-acting nasal sprays - but they're still being tested on animals.